Trailblazer Tracon raises $14 million to advance CD105 cancer therapy
This article was originally published in Scrip
Executive Summary
Tracon Pharmaceuticals, a six-year-old San Diego, California-based biotech developing targeted therapies for oncology and related diseases, has raised $14 million in the first tranche of a planned $22 million round of venture capital needed to advance TRC105, a promising monoclonal antibody that binds CD105, or endoglin, an endothelial cell membrane receptor essential for angiogenesis – the process of new blood vessel formation.